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Abstract The gene expression of the human GalL1,4(3)Glc-
NAc/GalL1,3GalNAcK-2,3-sialyltransferase was investigated in
the leukaemic cell lines HL60, K-562, MOLT-4, THP-1 and in
blood leucocytes. Five different transcripts were identified. In
HL60 and THP-1 cells the expression levels of two of these
changed during differentiation. Two potential AP1 binding sites
were detected in the promoter regions of the gene. THP-1 cells
contain proteins binding with higher affinities to these sequences
in the sialyltransferase gene than to the AP1 consensus sequence,
whereas nuclear extracts from HL60 cells have the opposite
affinity.
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1. Introduction
The sialyltransferase family consists of more than 15 en-
zymes with the common function of catalysing the transfer
of sialic acid from CMP-sialic acid to oligosaccharide chains
of glycolipids and glycoproteins [1,2]. Sialic acids function as
key determinants of oligosaccharide structures which mediate
a variety of biological phenomena [3,4]. With their negative
charge sialic acids mediate the binding of selectins [5,6]. A
more speci¢c function is ful¢lled in the mediation of cellular
interactions by CD22, CD33, MAG and sialoadhesin [6,7].
The di¡erent sialyltransferases can be classi¢ed enzymati-
cally by their acceptor substrate speci¢cities [1]. As one of the
cloned K2,3-sialyltransferases [8^13] the human ST3Gal IV is
able to transfer sialic acids to GalL1,3GalNAc and
GalL1,4GlcNAc. The cDNA of this sialyltransferase has
been cloned from the human melanoma cell line WM266-4
[12] and human placenta [9]. The gene is distributed over 14
exons which span at least 25 kb of genomic sequence and its
transcription results in ¢ve distinct mRNAs which are gener-
ated by alternative splicing and alternative promoter utilisa-
tion. The expression of di¡erent transcripts has also been
reported for the ST6Gal I [13,14]. The predicted promoter
region of the ST3GAl IV lacks TATA or CCAAT boxes
but contains consensus sequence of other regulatory elements
such as AP1 and HLH [15]. The AP1 consensus sequence is
recognised by Jun and Fos proteins. The interaction between
members of the Jun/Fos family generates a diversity of protein
complexes which regulate the expression of various genes.
Their a⁄nities depend on the formation of homo- compared
to heterodimers [16,17]. To date, only the ST6Gal I has been
analysed with regard to the involvement of liver-restricted
transcription factors in its expression [14].
In this study we investigated the expression of the ST3Gal
IV transcripts in leucocytes and the leukaemic cell lines K-
562, HL-60, THP-1 and MOLT-4. The presence and the tran-
scription start sites of the ¢ve transcripts were determined
with primer-extension analysis. Furthermore we investigated
whether the identi¢ed AP1 recognition sequences in the gene
of the ST3Gal IV were bound by nuclear proteins from the
di¡erent cell types.
2. Materials and methods
2.1. Materials
Oligonucleotides were purchased from Eurogentec, [Q-32P]ATP was
obtained from Hartmann and CMP-[14C]Neu5Ac from Amersham
and the direct-mRNA Kit from Qiagen was used. Polymorphprep
was obtained from Nycomed. SuperScript RT was ordered from Gib-
co BRL. Human placenta was obtained from the Universitaºts-Frauen-
klinik Kiel.
2.2. Cell culture
All cells were grown at 37‡C in a humidi¢ed atmosphere containing
5% CO2 in RPMI 1640 supplemented with 10% FCS and 2 mM
glutamine without antibiotics. Di¡erentiation of HL-60 cells to gran-
ulocyte-like cells was induced by treatment with 1.35% DMSO and of
both HL-60 and THP-1 cells to macrophages with 16 WM PMA. Cell
di¡erentiation was monitored by adhesion to culture plates, cell mor-
phology and nuclear staining (Wright).
2.3. Preparation of leucocytes
The mono- and the polymorphonuclear fractions of the leucocytes
were isolated from peripheral blood by density gradient centrifugation
with Polymorphprep (Nycomed). The purity of the leucocyte fractions
was about 95% as determined by cell staining (Wright).
2.4. Isolation of mRNA, primer-extension analysis and dot blots
The following oligonucleotides speci¢c for the di¡erent transcripts,
in parentheses, were used: 5P-GCT-GAG-GGC-TTG-ACC-CTG-
ATT-GTA-C-3P (A1), 5P-GAG-CTT-CCA-GCC-CAC-TGT-CCT-
TCA-A-3P (A2), 5P-AGC-GAC-CTT-GCG-ACT-CCT-GCA-CAC-A-
3P (B1), 5P-CAC-TGT-GTG-AGG-GCT-TGA-GTC-CTC-T-3P (B2),
5P-GGG-ACT-TGC-TGA-CCA-TGT-TTC-TCA-G-3P (B3). Up to
7 Wg mRNA was isolated from 2U107 cells with Oligotex direct
mRNA isolation kit from Qiagen and stored at 380‡C. The primer-
extension analysis was performed with 0.5 Wg mRNA, radiolabelled
oligonucleotides and SuperScript RT following the supplied protocol
with a 30 min extension step at 37‡C. The quantitative analysis of the
mRNA was performed by dot blot analysis with 5P-32P-oligonucleo-
tides following the protocol from Qiagen.
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2.5. EMSA
Electrophoretic mobility shift assays were performed with double-
stranded oligonucleotides (AP1100 : 5P-CTA-GGC-CGA-CTG-ACT-
AAT-GAT-C-3P, AP175 : 5P-TTC-TGC-AGT-GAC-TGC-AGC-
GTG-G-3P, AP168 : 5P-CGG-ATC-TGT-GAC-CTC-GTC-CTG-T-3P).
The indices represent the percentage of homology to the consensus
binding sequence for transcription factor AP1 [18]. AP175 was found
in the promoter region of B2, AP168 in that of A1, A2, B3. The
nuclear extracts were prepared from 5U108 cells according to a de-
scribed protocol [19]. Protein concentration was about 2.5 Wg/Wl.
Binding reactions were performed in a total volume of 20 Wl contain-
ing 1Ubinding bu¡er (100 mM NaCl, 4% glycerol, 10 mM Tris pH
7.5), 1 Wg dI-dC, 0.4 pmol of 32P-labelled double-stranded oligonu-
cleotide, 5^10 Wg of nuclear protein. Where indicated, up to 100-fold
excess of unlabelled competitor oligonucleotide was added. After
20 min incubation on ice, the mixture was loaded on a non-denaturing
polyacrylamide gel which was run at 100 V in 1UTGE, dried and
subjected to autoradiography for 2 h at 380‡C.
2.6. Sialyltransferase assays
Membranes were prepared from 107 sonicated cells by ultracentri-
fugation at 100 000Ug for 30 min (TLA-45) and resuspended in 100
Wl of 50 mM Na-cacodylate (pH 6.5, 5 mM MnCl2) bu¡er. The assays
were performed with lactose as acceptor substrate and contained 5 Wl
membrane suspension (140^160 Wg protein, with 1% Triton X-100,
50 nM Na-cacodylate, 5 mM MnCl2, 0.2 M lactose and 3 WM
CMP-[14C]Neu5Ac (10.8 Bq/pmol) in a total volume of 50 Wl). Reac-
tion mixtures were incubated for 45 min at 37‡C. Assays were per-
formed in ¢ve parallels and controls without lactose in duplicate. The
radioactive sialyllactose products were puri¢ed by anion-exchange
chromatography on Dowex 1U8, 200^400 mesh (phosphate form)
[20] and on Dowex 1U8 (formiate form) and eluted with 1.5 M formic
acid and total radioactivity was determined. Radioactive K2,3- and
K2,6-sialyllactoses were separated by TLC [21] and quanti¢ed on a
TLC linear analyser (Berthold).
3. Results
3.1. Analysis of the presence of the di¡erent transcripts and the
transcriptional start sites
Speci¢c oligonucleotides for the ¢ve di¡erent transcripts
A1, A2, B1, B2 and B3 were used together with freshly ex-
tracted mRNA from the cell lines HL-60, MOLT-4, K-562
and THP-1 and from peripheral blood leucocytes in a pri-
mer-extension analysis. In addition, the two cell lines HL60
and THP-1 were di¡erentiated with DMSO and/or PMA. The
existence of the ¢ve transcripts and the transcriptional start
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Fig. 1. Transcription start sites of the ¢ve transcripts. The transcription start sites were determined by primer-extension analysis with oligonu-
cleotides speci¢c for each transcript and mRNA from the cell lines and leucocytes as described in Section 2. The individual transcription start
sites of the indicated transcripts found in the di¡erent cell lines are marked with arrows. The sequences of the corresponding 5P-ends are given.
HL60 D stands for DMSO-treated HL60 cells, HL60 P and THP-1 P for PMA-treated HL60 and THP-1 cells, respectively. PolyL stands for
polymorphnuclear leucocytes and monoL for mononuclear leucocytes.
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sites were then determined by comparison of the product
length with the published sequences [15]. The results are
shown in Fig. 1.
The three transcripts A2, B1 and B2 are expressed in all
di¡erent cell types investigated, whereas the transcripts A1
and B3 could not be detected by this method in undi¡erenti-
ated HL60 and THP-1 cells. After treatment of these two cell
lines with PMA or DMSO, they also expressed the transcripts
A1 and B3.
The transcription does not seem to start at the same site in
the di¡erent cells investigated. In Fig. 1 only the start sites at
the very 5P-ends are shown.
3.2. Investigation on the time course of transcript expression in
di¡erentiated HL60 and THP-1 cells
In order to investigate the time course of expression, we
determined the relative amounts of the ¢ve transcripts in cells
harvested after di¡erent times of treatment with DMSO or
PMA (Fig. 2). The transcripts A1 and B3 which could not
be detected by primer extension analysis in undi¡erentiated
HL60 and THP-1 cells appeared already after 1 h of treatment
with DMSO or PMA. In DMSO-treated HL60 cells the ex-
pression of transcript A1 rapidly increased during the ¢rst 6 h
of treatment and then decreased, reaching almost background
level after 24 h. In contrast to this, the expression of transcript
B3 continuously increased during the 72 h of the experiment.
Also in HL60 cells incubated with PMA the expression of A1
increased rapidly to a 6.5-fold level within 6 h. In contrast to
DMSO-treated cells, the expression was maintained at the
higher level. The expression of B3 after 3 h of treatment
was only transient and decreased to a 2-fold level. The ex-
pression pattern in THP-1 cells treated with PMA was similar
to that in HL60 cells treated with PMA. But the expression of
A1 decreased slightly faster and of B3 only to a 3.5-fold level.
For the other transcripts no relevant changes during the in-
cubation time could be observed. Only the transcript A2
showed an increased expression in PMA-treated HL60 cells.
3.3. Sialyltransferase activity
In order to investigate whether the changes of transcript
expression levels observed after DMSO or PMA treatment
in£uence the enzyme activity, K2,3- and K2,6-sialyltransferase
activities were determined (Fig. 3). The activity of the K2,6-
sialyltransferase decreased during DMSO or PMA treatment,
whereas the activity of the K2,3-sialyltransferase remained at
the same level in THP-1 cells or increased slightly as observed
for HL60 cells. This increase in enzyme activity seems to
correlate with the elevated expression of A1, A2 and B3 found
for these cells.
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Fig. 2. Time course of transcript expression in HL60 and THP-1
cells. Poly(A) mRNA was extracted from di¡erentiated cells after
0^72 h of treatment with DMSO or PMA, 100 ng RNA was ap-
plied to nylon membranes, hybridised with probes speci¢c for each
transcript and bound radioactivity was quanti¢ed. The mean values
of triplicates are shown as relative changes of expression levels
against time.
Fig. 3. Sialyltransferase activity in HL60 and THP-1 cells. The
K2,3- (¢lled symbols) and K2,6-sialyltransferase (open symbols)
activities were determined in membrane suspensions of DMSO-
(circles) or PMA-treated (squares) HL60 and PMA-treated THP-1
cells (triangles) harvested at the time points as described in
Section 2.
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3.4. Binding of nuclear proteins to the AP1-like sequences
The 5P-£anking regions of the transcripts lack TATA or
CCAAT boxes, but they contain other well-characterised reg-
ulatory elements [15]. At two di¡erent positions AP1-like
binding sequences were detected. The identi¢ed recognition
sequences di¡er in two (AP175) or three bases (AP168) from
the consensus sequence [18]. We performed EMSAs with the
AP1 consensus sequence and the oligonucleotides AP175=68.
Fig. 4a shows the results of incubations of the oligonucleotide
AP168 with nuclear extracts from the di¡erent cell lines and
leucocytes. The highest binding of this oligonucleotide was
observed with extracts from THP-1 cells, followed by K-562
cells, whereas extracts from the other cell types showed only
weak binding. Strikingly, nuclear proteins from PMA-treated
THP-1 cells also bound weakly to AP168. A di¡erent situation
was observed in EMSAs with AP1100 as shown in Fig. 4b. In
this case the highest binding was detected with nuclear pro-
teins from HL60 cells. A comparison of the EMSAs with
AP168 and AP1100 revealed striking di¡erences. Nuclear pro-
teins from THP-1 cells showed a high a⁄nity to AP168 and
AP175 (not shown) and low a⁄nity to AP1100. For nuclear
extracts from HL60 cells the contrary was observed. They
exhibited a good binding to AP1100 and a lower a⁄nity to
the two other oligonucleotides. These di¡erences show that
di¡erent proteins exist which bind to the oligonucleotides
with speci¢c a⁄nities. To further elucidate this ¢nding,
cross-competition assays with nuclear extracts from HL60
and THP-1 cells and radioactively labelled AP1100 and
AP175 were performed. In the case of HL60 cells (Fig. 5a),
for the competition of labelled AP1100 to almost background
level a 10-fold excess of unlabelled AP1100 was su⁄cient to
reduce the binding, whereas a 100-fold excess of AP175 was
necessary before a reduction of the signal to a background
level could be observed. In contrast, nuclear extracts from
THP-1 cells showed a stronger a⁄nity to AP175, since this
was a more potent competitor than AP1100 (Fig. 5b).
4. Discussion
The analysis of transcription start sites by primer-extension
analysis revealed more than one start site in leucocytes and
leukaemic cell lines for all ¢ve transcripts. Similar results were
obtained by Kitagawa et al. [15] in human placenta. In Fig. 1
only the start sites at the very 5P-ends are shown. The rele-
vance of several start sites is not yet known. One reason for
this phenomenon might be a stuttering of the RNA polymer-
ase II, as suggested by Wang et al. [22] for the ST6Gal I.
Another possibility is the formation of secondary structures
in the mRNA which result in the interruption of cDNA syn-
thesis by RT. Therefore, in these cases only the start sites at
the very 5P-ends are thought to be relevant. However, the
variability of biological systems may lead to the usage of
more than one start site.
The transcripts A1 and B3 were only expressed at very low
levels in undi¡erentiated HL60 and THP-1 cells. Because of
this observation the time course of transcript expression dur-
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Fig. 4. EMSA with nuclear extracts and AP1 oligonucleotides. EMSAs with nuclear extracts from the di¡erent cell types were performed as de-
scribed in Section 2. Arrows indicate the retarded oligonucleotides bound to protein and unbound oligonucleotides. Abbreviations as in Fig. 1.
a: Assays with the oligonucleotide AP168. b: Assays with the oligonucleotide AP1100. The EMSAs with di¡erentiated cells and leucocytes were
similar to those with AP168.
Fig. 5. Cross-competition with nuclear extracts from HL60 and
THP-1 cells. EMSAs in the presence of unlabelled competing oligo-
nucleotides AP1100 (left) or AP175 (right) were performed as de-
scribed in Section 2. a: Nuclear proteins from HL60 cells were incu-
bated with radioactively labelled AP1100. b: Nuclear proteins from
THP-1 cells were incubated with radioactively labelled AP175.
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ing treatment with DMSO or PMA was investigated. After 1 h
treatment these transcripts could be detected and expression
levels changed during incubation. Except for A2 the other
transcripts were expressed more or less at the same level
throughout the experiment. This aspect may result from the
usage of the same promoter for A2 as for transcript A1. The
transcript A2 lacks the exon E5 and therefore encodes a trun-
cated protein without cytoplasmic tail and only a short puta-
tive signal anchor domain [9]. This may have an in£uence on
the targeting of the sialyltransferase to Golgi compartments.
However, signals which de¢ne the localisation of glycosyl-
transferases within the Golgi have not been de¢nitively deter-
mined [23,24]. Transcript A1 possibly also encodes a trun-
cated protein, since three di¡erent in-frame start codons
were identi¢ed and according to Kozak [25] the third start
codon represents the strongest one.
In HL60 cells changes in the expression levels of transcripts
led to a small increase of the K2,3-sialyltransferase activity.
In a previous study [26] no such increase of this enzyme ac-
tivity was detected for DMSO-treated HL60 cells. This could
be due to the use of total cell lysates in those experiments,
which may contain endogenous inhibitors. Here we puri¢ed
membranes as enzyme source and took special care to use
conditions under which the product formation was linear de-
pendent on both the amount of membranes and the time of
incubation.
The predicted promoter region does not contain TATA or
CCAAT boxes [15], which is believed to be typical of so-called
housekeeping genes expressed in almost all tissues at low lev-
els [27]. We directed our interest to the involvement of the
transcription factor AP1 in the regulation of the gene, since it
contains two AP1-like sequences. We observed that nuclear
proteins from HL60 and THP-1 cells recognise the AP1 con-
sensus sequence and homologous sequences with di¡erent af-
¢nities. The gene products of the Jun/Fos family are expressed
in HL60 cells treated with PMA for a short period of time
and are just detectable after several hours [28]. The fast in-
crease of the transcripts A1/A2 and B3 can possibly be corre-
lated to this ¢nding. Noti et al. [29] observed a cooperation
between SP1 and AP1 in myeloid cells. In undi¡erentiated
cells this cooperation was not detectable, whereas in PMA-
treated cells the binding of AP1 was facilitated under the
in£uence of SP1. In this respect low amounts of Jun and
Fos may guarantee the expression of ST3Gal IV transcripts,
whereas at the beginning of di¡erentiation without the sup-
port of SP1 higher amounts of Jun/Fos gene products are
required.
In conclusion, this study shows the di¡erential expression of
ST3Gal IV transcripts in human leucocytes. Strikingly, THP-1
cells contain in contrast to HL60 cells nuclear proteins bind-
ing to the AP1-like elements in the promoter regions of this
gene with higher a⁄nities than to the AP1 consensus se-
quence. Therefore, these promoter regions represent a suitable
model to identify and compare the constituents of AP1 dimers
in THP-1 and HL60 cells.
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